
vTv Therapeutics VTVT
$ 38.0
-3.89%
Quarterly report 2023-Q2
added 08-11-2023
vTv Therapeutics Depreciation & Amortization 2011-2026 | VTVT
Annual Depreciation & Amortization vTv Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 92 K | 89 K | 94 K | 39 K | 218 K | 197 K | 265 K | 501 K | 864 K | 1.09 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.09 M | 39 K | 344 K |
Quarterly Depreciation & Amortization vTv Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 22 K | - | 69 K | 45 K | 23 K | - | 67 K | 45 K | 23 K | - | 72 K | 49 K | 27 K | - | 24 K | 16 K | 8 K | - | 111 K | 81 K | 42 K | - | 152 K | 104 K | 52 K | - | 216 K | 148 K | 79 K | - | 361 K | 247 K | 133 K | - | 681 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 681 K | 8 K | 111 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.34 | -3.6 % | $ 357 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
2.99 M | $ 20.13 | -1.13 % | $ 2.81 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.57 | -3.57 % | $ 16.1 M | ||
|
Equillium
EQ
|
116 K | $ 2.04 | 1.24 % | $ 117 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Fate Therapeutics
FATE
|
12.9 M | $ 1.13 | -5.04 % | $ 134 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Forte Biosciences
FBRX
|
64 K | $ 26.57 | 0.49 % | $ 344 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Foghorn Therapeutics
FHTX
|
3.33 M | $ 4.74 | -2.87 % | $ 299 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Amicus Therapeutics
FOLD
|
7.46 M | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Fulcrum Therapeutics
FULC
|
1.39 M | $ 7.55 | -3.58 % | $ 478 K | ||
|
Galectin Therapeutics
GALT
|
1 K | $ 2.25 | -12.3 % | $ 144 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Gilead Sciences
GILD
|
370 M | $ 138.19 | -1.38 % | $ 172 B | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.61 | -3.59 % | $ 189 M | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.5 | -1.13 % | $ 236 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
42 K | $ 0.54 | 4.26 % | $ 503 K | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 314.44 | -4.81 % | $ 41.2 B | ||
|
Gossamer Bio
GOSS
|
24 K | $ 0.32 | -7.11 % | $ 73.1 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
GT Biopharma
GTBP
|
4 K | $ 0.42 | -6.49 % | $ 2.32 M | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Halozyme Therapeutics
HALO
|
11.4 M | $ 63.51 | 0.68 % | $ 7.61 B |